ClinicalTrials.gg
RecruitingNCT05785026MENTHODYSCUpdated Nov 19, 2025

Menthol for Dyspnea Relief in Health and COPD

An interventional study of Menthol inhalation and Strawberry scent in Dyspnea and Chronic Obstructive Pulmonary Disease, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by KU Leuven · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Dyspnea with a site in Belgium — 3 open to participants now, 3 under way, none of them phase 3. Dyspnea · Belgium.

Planned enrollment
7th of 13
120 · median 120
Started
2023
the only one that year
No phase
5 of 19
2 open now
Registered
16th of 19
by date
Lead sponsor
3 of 19
KU Leuven

Among the 19 studies in Dyspnea with a site in Belgium, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 5 with no phase, and was the 16th registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

3 of the 19 studies in Dyspnea with a site in Belgium are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dyspnea with a site in Belgium, or all of them as a file.
02

Study summary

Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and/or neural related mechanisms for this relief in symptoms remain unknown. The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.

Read the detailed description

The project is structured in 5 work packages (WP), each including a different sample of healthy volunteers (WP1, 2) or patients with COPD (WP3, 4, 5), respectively with a 1:1 female/male ratio in each WP. Each WP will be single-blind, placebo-controlled cross-over trial to investigate the effects of MI compared to placebo in healthy volunteers during resistive loaded breathing (WP1), in healthy volunteers during cycling exercise (WP2), in people with COPD who have dyspnea at rest (WP3), and in people with COPD during cycling exercise (WP4, 5).

03

Conditions studied

  • Dyspnea
  • Chronic Obstructive Pulmonary Disease

Keywords

  • Menthol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years of age or older
  • Able to speak, read, and write Dutch or English
  • Normal pulmonary function: (FEV1) to forced vital capacity ratio>0.70; FEV1≥80%predicted (WP1 and 2 only)
  • Non-smoker or former smokers (smoke-free ≥12 months prior to enrolment) (WP1 and 2 only)
  • Clinically stable (based on clinical judgment of the study physician that have not had exacerbations requiring escalation of medical therapy (i.e., short course of oral or antibiotics) within the preceding 14 days (WP3 and 4 only)

Exclusion criteria

Exclusion Criteria:

  • to exercise testing (e.g., significant cardiovascular, musculoskeletal, neurological disease; see Table 4 from ERS/ATS consensus statement)
  • Significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could influence dyspnea and/or impair exercise capacity (with the exception of in WP3 and 4)
  • \<18.5 or >35 kg/m2
  • An ulcer or tumor in the esophagus, a nasal septum deviation, or recent nasopharyngeal surgery
  • Severe facial trauma including cribriform plate disruption (bone separating brain from nasal cavity)
  • Allergies to latex and sensitivities to local anesthetics
  • Inability to give , including those with significant cognitive impairment
  • Alcohol consumption within 12 hours of study visit
  • Current smoker*
  • History of early menopause (age \<45 years)
  • Pregnancy or desire to become pregnant while in trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    WP 1a

    Menthol inhalation during resistive loaded breathing trials in healthy participants.

    Other: Menthol inhalation

  • Placebo comparator
    WP 1b

    Strawberry scent during resistive loaded breathing trials in healthy participants.

    Other: Strawberry scent

  • Experimental
    WP 2a

    Menthol inhalation during cycle exercise in healthy participants.

    Other: Menthol inhalation

  • Placebo comparator
    WP 2b

    Strawberry scent during cycle exercise in healthy participants.

    Other: Strawberry scent

  • Experimental
    WP 3a

    Menthol inhalation during resting breathing in dyspneic COPD participants.

    Other: Menthol inhalation

  • Placebo comparator
    WP 3b

    Strawberry scent during resting breathing in dyspneic COPD participants.

    Other: Strawberry scent

  • No intervention
    WP 3c

    Resting breathing in dyspneic COPD participants.

  • Experimental
    WP 4a

    Menthol inhalation during cycle exercise in COPD participants.

    Other: Menthol inhalation

  • Placebo comparator
    WP 4b

    Strawberry scent during cycle exercise in COPD participants.

    Other: Strawberry scent

  • Experimental
    WP 5a

    Menthol inhalation and facial airflow during cycle exercise in COPD participants

    Other: Menthol inhalation and facial airflow

  • Placebo comparator
    WP 5b

    Strawberry inhalation and airflow to leg during cycle exercise in COPD participants

    Other: Strawberry scent and airflow to leg

  • Placebo comparator
    WP 5c

    Menthol inhalation and airflow to leg during cycle exercise in COPD patients

    Other: Menthol inhalation and airflow to leg

  • Placebo comparator
    WP 5d

    Strawberry inhalation and facial airflow during cycle exercise in COPD patients

    Other: Strawberry inhalation and facial airflow

Interventions

  • OtherMenthol inhalation

    300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.

  • OtherStrawberry scent

    600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.

  • OtherMenthol inhalation and facial airflow

    Menthol will be administered using a noseplug and facial airflow will be applied with a tabletop fan.

  • OtherStrawberry scent and airflow to leg

    Strawberry will be administered using a noseplug and airflow to the leg will be applied with a tabletop fan.

  • OtherMenthol inhalation and airflow to leg

    Menthol will be administered using a noseplug and airflow to the leg will be applied with a tabletop fan.

  • OtherStrawberry inhalation and facial airflow

    Strawberry will be administered using a noseplug and facial airflow will be applied with a tabletop fan.

06

What researchers measure

Primary outcomes

  1. Difference in respiratory-related evoked potentials (RREP) with menthol vs. strawberry.

    RREPs will be measured using an electroencephalogram (EEG) sensor cap connected to a high-density 129 channel EEG system during breathing trials and exercise tests. Inspiration will briefly be interrupted for 150 milliseconds every two to six breaths by activation of the occluder, which induces the RREP in the EEG signal.

    Time frame: 1 week

Other outcomes

  1. Difference in diaphragmatic electromyography with menthol vs. strawberry.

    Diaphragmatic electromyography will be measured using a multi-pair electrode catheter during breathing trials and exercise tests. and used as an index of neural respiratory drive.

    Time frame: 1 week

  2. Difference in dyspnea with menthol vs. strawberry (+ facial airflow or airflow to leg in WP5).

    Dyspnea ratings will be measured using the Borg 0-10 category ratio scale and will be assessed at the end of each 5-minute breathing trial (WP1 and 3), and at baseline, every minute during (WP4,5) or halfway through the test (WP2), and at peak of each cycle exercise test. 0 represents no dyspnea at all and then 10 the most maximal dyspnea ever experienced or could be imagined experiencing.

    Time frame: 1 week

  3. Difference in the rate of perceived inspiratory airflow.

    Participants will be asked: "In which of the four conditions did your airflow feel easier when breathing in?" at the end of each study visit.

    Time frame: 1 week

  4. Perception of a cooling sensation.

    Participants will be asked: "In which of the four conditions did you feel a fresh or cooling sensation when breathing in?" at the end of each study visit.

    Time frame: 1 week

  5. Difference in activation of extra-diaphragmatic inspiratory muscles with menthol vs. strawberry.

    Activation of extra-diaphragmatic inspiratory muscles will be measured using bipolar surface electrodes during breathing trials (WP3) and exercise testing (WP4).

    Time frame: 1 week

  6. Difference in the cardiorespiratory responses to exercise with menthol vs. strawberry.

    Cardiorespiratory responses to exercise will be measured on a breath-by-breath basis using a commercially available cardiopulmonary testing system during exercise testing.

    Time frame: 1 week

  7. Difference in respiratory pressures with menthol vs. strawberry.

    Respiratory pressures will be measured using esophageal and gastric balloons during breathing trials and exercise testing.

    Time frame: 1 week

  8. Difference in leg discomfort ratings with menthol vs. strawberry (+facial airflow or airflow to leg in WP5).

    Leg discomfort will be measured using the Borg 0-10 category ratio scale at baseline, every minute during (WP4, 5) or halfway through the test (WP2), and at peak of each cycle exercise test. 0 represents no leg discomfort at all and then 10 the most maximal leg discomfort ever experienced or could be imagined experiencing.

    Time frame: 1 week

  9. Difference in exercise endurance time with menthol vs. strawberry (+ facial airflow or airflow to leg in WP5).

    Exercise endurance time will be measured during submaximal constant load cycle exercise testing (WP4, 5).

    Time frame: 1 week

  10. Difference in the reasons for stopping exercise with menthol vs. strawberry (+facial airflow or airflow to leg in WP5).

    Participants will be asked to give their reasons for stopping (e.g., "breathing discomfort," "leg discomfort," "a combination of breathing and leg discomfort," or "other") and attributing a percentage to each of breathing discomfort and leg discomfort to total 100 (WP 2, 4 and 5).

    Time frame: 1 week

  11. Difference in ratings of affective state on the dimensions of valence and arousal with menthol vs. strawberry (+ facial airflow or airflow to leg in WP5).

    Dimensions of valence and arousal will be measured using the 9-point Self-Assessment Manikin scale for valence (1 -"unpleasant" to 9 -"pleasant") and arousal (1-"calm" to 9-"aroused") at the end of each breathing trial (WP 1 and 3) and at peak exercise (WP 2, 4 and 5).

    Time frame: 1 week

  12. Difference in the Neural Drive to Breathe (P0.1)

    The neural drive to breathe will be measured using airway occlusion pressure (P0.1), evoked by inspiratory occlusions delivered during the test (WP1 and 2).

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Schaeffer MR, Vanden Bossche L, Beckers K, Verbeke K, Janssens W, Jensen D, Arnold JI, von Leupoldt A, Langer D. Inhaled Menthol for Dyspnea Relief During Cycle Exercise in COPD: A Randomized Trial. Chest. 2025 Aug;168(2):390-401. doi: 10.1016/j.chest.2025.03.002. Epub 2025 Mar 13. PubMed 40088943 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Oct 2028, 69 months after the start.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 69 months is above that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2023
First posted
Mar 27, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05785026
Lead sponsor
KU Leuven
Responsible party
Daniel Langer (Assistant Professor, KU Leuven) — Principal investigator
First posted
Mar 27, 2023
Start date
Jan 1, 2023
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 19, 2025

Study contacts

Daniel Langer
Contact
daniel.langer@kuleuven.be
+32 16 37 64 97
Daniel Langer
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion